Lilly's Omvoh Meets Primary Endpoint In Phase 3 Pediatric Ulcerative Colitis Study
(RTTNews) - One in two pediatric ulcerative colitis patients who responded to initial treatment with Omvoh remained in clinical remission after one year in a Phase 3 study, as Eli Lilly and Company (LLY) reported positive results from the SHINE-2 trial evaluating the therapy in c